Indoco Remedies Unit Gains EU GMP Certification

The Baddi Unit-I of Indoco Remedies has secured EU GMP (Good Manufacturing Practice) certification, a significant endorsement of its manufacturing quality. The certification follows a successful inspection by the Malta Medicines Authority from January 29 to February 03, 2026, confirming the facility meets the stringent quality and safety standards required by European Union regulations. This development is crucial for the pharmaceutical company, which reported a US$175 million turnover.

Managing Director Aditi Panandikar highlighted the achievement as a testament to the company's commitment to global quality standards. Obtaining EU GMP certification is essential for pharmaceutical companies looking to export to EU countries, signaling adherence to the highest international benchmarks for drug manufacturing.

This approval is expected to enhance the Baddi facility's credibility and position Indoco Remedies to secure new export orders from European nations. It may also allow the company to bid on a broader range of pharmaceutical products in the EU, reinforcing its reputation as a reliable, high-quality global supplier. The Baddi plant plays a central role in Indoco's production of solid oral dosage forms, a key business segment, and this certification supports the company's strategy to expand its international presence.

The European generics market is highly competitive, demanding ongoing innovation and cost management. Maintaining strict adherence to EU GMP standards will be crucial to preserve the certification and avoid future compliance issues.

Major Indian pharmaceutical companies such as Cipla, Sun Pharma, and Lupin also operate EU GMP-certified manufacturing sites to serve the European market with formulations and APIs. Indoco Remedies' Baddi facility now aligns more closely with these peers in terms of European regulatory compliance.

Investors will be looking for actual growth in EU export orders, new product launches in Europe facilitated by the Baddi facility, further certifications for other Indoco units, and management's commentary on strategic expansion plans stemming from this approval.